News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

The Female Health Company to Report Third Quarter Operating Results on Tuesday, July 31, 2012



7/24/2012 12:06:59 PM

CHICAGO, July 24, 2012 /PRNewswire/ -- The Female Health Company (NASDAQ-CM: FHCO - News) today announced that it will host an investor conference call to discuss its operating results for the third quarter and first nine months of FY2012 on Tuesday, July 31, 2012 at 11:00 a.m. Eastern Time (EDT). The Company expects to report its operating results earlier the same day.

(Logo: http://photos.prnewswire.com/prnh/20120712/MM39764LOGO)

Shareholders and other interested parties may participate in the conference call by dialing 1-877-374-8416 (international participants dial 1-412-317-6716) and asking to be connected to "The Female Health Company Conference Call" a few minutes before 11:00 a.m. EDT on July 31, 2012. A replay of the call will be available one hour after the call through 9:00 a.m. EDT on Tuesday, August 14, 2012 by dialing 877-344-7529 (international callers dial 412-317-0088) and entering the conference ID 10016803.

About The Female Health Company

The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 FemaleCondom®(FC2), which is available in the U.S. and in about 130 other countries globally. The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in the U.S., the European Union, Canada, Australia, South Africa, Japan, The People's Republic of China, Spain, Mexico, Greece, Turkey and the African Regional Intellectual Property Organization (ARIPO), which includes Botswana, The Gambia, Ghana, Kenya, Lesotho, Malawi, Mozambique, Namibia, Sierra Leone, Somalia, Sudan, Swaziland, Uganda, United Republic of Tanzania, Zambia and Zimbabwe. FC2 patent applications are pending in various countries. The FC2 Female Condom® is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

The statements in this release which are not historical facts are forward-looking statements based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.

For more information about The Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to FHCInvestor@femalehealthcompany.com .

SOURCE The Female Health Company


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES